PubRank

Robin Thorpe

Author PubWeight™ 38.16‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Biosimilars: what clinicians should know. Blood 2012 2.28
2 "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007 2.11
3 Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002 1.86
4 Biosimilars-why terminology matters. Nat Biotechnol 2011 1.73
5 In support of the European Union biosimilar framework. Nat Biotechnol 2012 1.33
6 Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 2009 1.12
7 Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008 1.11
8 How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response. Cytokine 2013 1.08
9 Cytokine gene expression in a murine wound healing model. Cytokine 2005 1.04
10 Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol 2013 0.96
11 Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods 2009 0.95
12 In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine 2010 0.89
13 Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett 2002 0.87
14 European perspective on biosimilars. Bioanalysis 2013 0.87
15 An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J Interferon Cytokine Res 2010 0.86
16 Haematopoietic growth factors and their therapeutic use. Thromb Haemost 2008 0.86
17 WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24-26 August, 2010. Biologicals 2011 0.85
18 Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine 2011 0.85
19 Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis 2010 0.84
20 Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method. Biologicals 2005 0.83
21 Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan 1. Inflamm Bowel Dis 2010 0.83
22 Strategies and assays for the assessment of unwanted immunogenicity. J Immunotoxicol 2006 0.83
23 Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J Immunol Methods 2011 0.82
24 The 2nd International Standard for human granulocyte colony stimulating factor. J Immunol Methods 2011 0.82
25 Antibody C region influences TGN1412-like functional activity in vitro. J Immunol 2012 0.81
26 Comparison of toxicogenomic profiles of two murine strains treated with HIV-1-based vectors for gene therapy. Toxicol Appl Pharmacol 2007 0.81
27 The challenges of immunogenicity in developing biosimilar products. IDrugs 2009 0.80
28 Anti-D and anti-i activities are inseparable in V4-34-encoded monoclonal anti-D: the same framework 1 residues are required for both reactivities. Transfusion 2008 0.79
29 Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay. Cytokine 2010 0.79
30 The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol 2003 0.78
31 Are neutralizing anti-GM-CSF autoantibodies present in all healthy persons? Blood 2010 0.78
32 Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples. J Immunol Methods 2013 0.77
33 Characterization of complete particles (VSV-G/SIN-GFP) and empty particles (VSV-G/EMPTY) in human immunodeficiency virus type 1-based lentiviral products for gene therapy: potential applications for improvement of product quality and safety. Hum Gene Ther 2008 0.77
34 Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β. J Interferon Cytokine Res 2013 0.76
35 Establishment of a novel cell line for the enhanced production of recombinant adeno-associated virus vectors for gene therapy. Hum Gene Ther 2014 0.76
36 Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule. Biologicals 2004 0.76
37 Evaluation of similar biotherapeutic products: scientific and regulatory challenges. Biologicals 2011 0.75
38 A systematic approach to the establishment and characterization of endothelial progenitor cells for gene therapy. Hum Gene Ther Methods 2013 0.75
39 Biosimilars need comparative clinical data. Kidney Int 2011 0.75
40 WHO international cytokine standards and reference preparations. J Leukoc Biol 2010 0.75
41 World health Organization international cytokine standards and reference preparations. J Interferon Cytokine Res 2010 0.75
42 The 2nd International Standard for Interleukin-2 (IL-2). Report of a collaborative study. J Immunol Methods 2013 0.75
43 The 1st International standard for transforming growth factor-β3 (TGF-β3). J Immunol Methods 2012 0.75
44 WHO International Cytokine Standards and reference preparations. Cytokine 2010 0.75
45 Proteomics analysis of cellular components in lentiviral vector production using Gel-LC-MS/MS. Proteomics Clin Appl 2007 0.75